Meihao Medical Group Co., Ltd. (MEIHAO GROUP, 01947.HK) announced that, based on unaudited management accounts for the year ended 31 December 2025, the company anticipates a net loss of approximately RMB13.10 million to RMB19.80 million. This represents an improvement of 39%–59% from the RMB32.60 million loss recorded in FY2024.

Management attributes the reduced loss to four main factors:

1. Revenue Expansion and Economies of Scale • Larger operating scale diluted fixed costs such as depreciation and rent, increasing overall profitability.

2. Lower Share-Based Payment Expenses • A notable decline in equity-compensation outlays lessened non-cash expenses.

3. Streamlined Human Resources • Ongoing optimisation of staff allocation improved per-capita efficiency, reducing remuneration as a share of revenue.

4. Enhanced Cost Controls • Stricter expense management and operational efficiency initiatives curbed operating costs.

Despite the anticipated loss, the group reports maintaining a healthy financial position with adequate cash reserves. Final audited results for FY2025 are scheduled for release by end-March 2026. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.